Onset of Tuberculosis from a Pulmonary Latent Tuberculosis Infection during Antiviral Triple Therapy for Chronic Hepatitis C-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Onset of Tuberculosis from a Pulmonary Latent Tuberculosis Infection during Antiviral Triple Therapy for Chronic Hepatitis C

Published:2016 Issue:15 Volume:55 Page:2011-2017
ISSN:0918-2918
Container-title:Internal Medicine
language:en
Short-container-title:Intern. Med.

Author:

Matsuoka Shunichi¹,Fujikawa Hirotoshi²,Hasegawa Hiromasa³,Ochiai Takanaga³,Watanabe Yukinobu¹,Moriyama Mitsuhiko¹

Affiliation:

1. Division of Gastroenterology and Hepatology, Department of Medicine, Nihon University School of Medicine, Japan

2. Department of Gastroenterology and Hepatology, Japan Community Health Care Organization Yokohama Central Hospital, Japan

3. Department of Oral Pathology, Matsumoto Dental University, Japan

Publisher

Japanese Society of Internal Medicine

Subject

General Medicine,Internal Medicine

Link

https://www.jstage.jst.go.jp/article/internalmedicine/55/15/55_55.6448/_pdf

Reference19 articles.

1. 1. Jacobson IM, Gordon SC, Kowdley KV, et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med 368: 1867-1877, 2013.

2. 2. Lawitz E, Poordad FF, Pang PS, et al. Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial. Lancet 383: 515-523, 2014.

3. 3. Liaw YF, Jia JD, Chan HL, et al. Shorter durations and lower doses of peginterferon alfa-2a are associated with inferior hepatitis B e antigen seroconversion rates in hepatitis B virus genotypes B or C. Hepatology 54: 1591-1599, 2011.

4. 4. Escudier B, Pluzanska A, Koralewski P, et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 370: 2103-2111, 2007.

5. 5. Hu KQ, Tong MJ. The long-term outcomes of patients with compensated hepatitis C virus-related cirrhosis and history of parenteral exposure in the United States. Hepatology 29: 1311-1316, 1999.

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Type I interferon exacerbates Mycobacterium tuberculosis induced human macrophage death;EMBO Reports;2024-06-12

2. Interferon Upregulation Associates with Insulin Resistance in Humans;Current Diabetes Reviews;2024-03-18

3. Neutrophil‐plasmacytoid dendritic cell interaction leads to production of type I IFN in response to Mycobacterium tuberculosis;European Journal of Immunology;2023-12-31

4. Pathogenicity of Type I Interferons in Mycobacterium tuberculosis;International Journal of Molecular Sciences;2023-02-15

5. Mycobacterium tuberculosis MmsA (Rv0753c) Interacts with STING and Blunts the Type I Interferon Response;mBio;2020-12-22

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3